Clinical outcomes such as bleeding are rare in patients followed in anticoagulation clinics if warfarin therapy is closely monitored and individualised, and in these cases genetic testing does not significantly improve the safety of the drug. VKAs were initiated with either a genotype-guided algorithm or clinically-guided algorithm that included clinical variables and genotyping for CYP2C9 and VKORC1, or a dosing algorithm that included only clinical variables for the first days. Start here. Mateja Kaja Jezovnik, MD. Lastly, a meta-analysis was published in by Stergiopoulos and colleagues, which included nine randomized controlled trials and patients, and compared genotype-guided initial dosing of warfarin and its analogues to clinical dosing protocols. Clin Pharmacol Ther. J Thromb Haemost ; 9. Other currently available literature related to the use of pharmacogenomic testing in the initiation of warfarin therapy also does not show improved outcomes in either safety nor efficacy with warfarin therapy and therefore does not support the routine use of pharmacogenomic testing when initiating warfarin therapy
Testing for the select, informative CYP2C9 and VKORC1 single nucleotide polymorphisms is straightforward and the International Warfarin Pharmacogenetics. Pharmacogenomics. Mar;11(3) doi: /pgs Role of warfarin pharmacogenetic testing in clinical practice.
Clinical relevance of the pharmacogenetics of warfarin
Tan GM(1), Wu E, Lam YY. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?
Mohamed H.A. Shahin and Julie A. Johnson. Additional article.
Therefore, clinicians should be aware of the impact pharmacogenetic testing results can have on warfarin dose adjustments and use this information, should it be available.
No account yet?
Student Societies. Clin Pharmacol Ther.
Video: Coumadin pharmacogenetic testing Warfarin Pharmacogenetics
J Thromb Haemost ; 9.
PharmacoEconomics. ; – Warfarin has a narrow therapeutic window and a large variation in dose ROUTINE PHARMACOGENETIC TESTING to guide warfarin dosing as there is.
Identify an appropriate warfarin initiation strategy for a patient undergoing hip or knee arthroplasty given the results of the GIFT trial. N Engl J Med ; 4. Read your latest personalised notifications Sign in No account yet? The second determinant of variability in sensitivity to warfarin appears to be related to different genetic polymorphisms in the C1 sub-unit of the vitamin K 2,3 epoxide reductase complex.
specific therapy will not be effective.1 Warfarin is an ideal drug target for the application of pharmacogenetic testing due to its narrow therapeutic index, large .
Did you know that your browser is out of date?
Submit for CE. Pharmacists should be aware of advances in pharmacogenetic dose adjustments of medications to serve as a resource for both other healthcare providers and patients. To get the best experience using our website we recommend that you upgrade to a newer version.
FREE JAVA JRE DOWNLOAD
|However, pharmacogenetic testing comes at a cost.
A randomized, double-blind, controlled trial. Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? In addition, cost-effectiveness studies have also produced opposing results. Johnson J.